CD8A and neoplasm: DCs are able to capture, process, and present tumor-associated antigens (TAA) [146], which induce and activate a specific tumor immune response by presenting these antigens to T cells [105,110], as T helper cells (CD4+ T cells) and cytotoxic T cells (CD8+ T cells) [105] that can secrete cytokines to induce tumor rejection, such as IFN-γ [146], which can trigger and control an antitumor immune response [146].